phase II
From mutation to medicine – Abliva breaks new ground
Swedish biotechnology company Abliva continues to consolidate its leading role in the development of treatments for mitochondrial diseases. In Q3 2024...
Aqilion's CEO: "We are driven by dealmaking and scientific data"
With four standalone programs in its pipeline,...
Issuance drives Annexin's progress towards Phase II results
Phase II data in the eye disease retinal vein occlusion is approaching...
Annexin CEO: “The chances of success for ANXV have increased”
With a fully recruited phase II study in the eye disease retinal...
Annexin's Phase II study completed with positive signals
Annexin Pharmaceuticals has announced that the last patient...
Annexin towards completion of phase II study and issuance
After reporting promising efficacy signals in the...
Abliva reaches patient inclusion goals
For the biotechnology company Abliva, the main focus in 2023 has been...
Annexin's rights issue will take the company towards important milestones
Annexin Pharmaceuticals is conducting a fully secured rights issue of...
Intensive Q4 leads Annexin into interesting 2023
Intense and significant – that's how Annexin Pharmaceuticals describes...
Drug Development – The Four Steps
1. Discovery
Curasight optimistic about phase II results in brain cancer
When CEO Ulrich Krasilnikoff looks back on the time...
Issue advances ExpreS2ion's vaccine candidates
Biotechnology company ExpreS2ion Biotech advances its position on...